These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30076608)

  • 1. Improving anticancer activity towards colon cancer cells with a new p53-activating agent.
    Raimundo L; Espadinha M; Soares J; Loureiro JB; Alves MG; Santos MMM; Saraiva L
    Br J Pharmacol; 2018 Oct; 175(20):3947-3962. PubMed ID: 30076608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
    Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
    Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents.
    Lemos A; Gomes AS; Loureiro JB; Brandão P; Palmeira A; Pinto MMM; Saraiva L; Sousa ME
    Molecules; 2019 May; 24(10):. PubMed ID: 31121972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells.
    Gong EY; Shin YJ; Hwang IY; Kim JH; Kim SM; Moon JH; Shin JS; Lee DH; Hur DY; Jin DH; Hong SW; Lee WK; Lee WJ
    Toxicol Lett; 2016 Sep; 258():126-133. PubMed ID: 27339904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin.
    Ravizza R; Gariboldi MB; Passarelli L; Monti E
    BMC Cancer; 2004 Dec; 4():92. PubMed ID: 15601469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
    Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
    Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
    Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
    Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
    Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
    Abdel-Rahman WM; Al-Khayyal NA; Nair VA; Aravind SR; Saber-Ayad M
    World J Gastroenterol; 2017 May; 23(19):3440-3448. PubMed ID: 28596680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
    Cheok CF; Dey A; Lane DP
    Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
    Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of p53 by adenovirus type 12 E1B-55K deregulates cell cycle control and sensitizes tumor cells to genotoxic agents.
    Li Q; Zhao LY; Zheng Z; Yang H; Santiago A; Liao D
    J Virol; 2011 Aug; 85(16):7976-88. PubMed ID: 21680522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.
    Carvajal D; Tovar C; Yang H; Vu BT; Heimbrook DC; Vassilev LT
    Cancer Res; 2005 Mar; 65(5):1918-24. PubMed ID: 15753391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.